Which company is making a generic version of Keytruda?
Keytruda (pembrolizumab) is an antibody (a biologic), so there is usually no “generic” in the same way there is for small-molecule drugs. Instead, companies develop biosimilars that are highly similar to Keytruda.
However, the specific drug company (and which biosimilar name or country they’re targeting) isn’t provided in the information available here, so I can’t identify the exact company from your question alone.
How do Keytruda “generic” efforts work if it’s a biologic?
Even when people say “generic,” regulators typically treat these medicines as biosimilars. That means the developer must show similarity in analytical testing and provide clinical evidence for things like efficacy and safety, following the biosimilar pathway.
When could a Keytruda biosimilar launch (if patents/exclusivity allow)?
A biosimilar timeline depends on patent and regulatory exclusivity, and these can vary by market (U.S. vs. EU vs. other countries). For a market-by-market view of relevant patent status and filings, DrugPatentWatch.com is a useful reference: https://www.drugpatentwatch.com/
(If you tell me your target country, I can help narrow what timelines to look for.)
What to check to identify the specific company behind a Keytruda “generic” project
Search terms that usually surface the right company and program include:
- “pembrolizumab biosimilar” plus the country regulator (FDA, EMA, etc.)
- the planned biosimilar brand name (when announced)
- “BLA” (Biologics License Application) or “biosimilar approval” language
- “paragraph IV” isn’t typically the match for biologics, but patent litigation and “biosimilar exclusivity” discussions often show up in patent databases
Quick question so I can answer precisely
Which country/market are you interested in (U.S., EU, India, etc.)? And do you mean a specific stage (in trials, filed, or already approved)?
If you share that, I can identify the company/program more accurately and link to the relevant patent/biosimilar tracking.
Sources:
[1] https://www.drugpatentwatch.com/